Cannabinoids May Communicate Between Brain Cells Via Tiny Vesicles, Opening New Treatment Possibilities

A review proposes that endocannabinoids and phytocannabinoids interact with extracellular vesicles to form a signaling network that shapes vulnerability to neuropsychiatric disorders.

Marques, Bruno L et al.·Pharmaceuticals (Basel·2025·Preliminary EvidenceNarrative Review
RTHC-07055Narrative ReviewPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Emerging evidence indicates a bidirectional relationship: endocannabinoids can be loaded into extracellular vesicles for intercellular signaling, while THC and CBD alter EV release and cargo composition. The authors propose this interplay as a framework for developing biomarker-guided, personalized treatments for depression, anxiety, schizophrenia, and neurodegenerative diseases.

Key Numbers

Review covers evidence across depression, anxiety, schizophrenia, and neurodegenerative diseases. Discusses both THC and CBD effects on extracellular vesicle biology.

How They Did This

Hypothesis-driven narrative review searching PubMed, Scopus, and Web of Science through September 2025. The review focuses on the interface between cannabinoid signaling and extracellular vesicle biology in neuropsychiatric conditions.

Why This Research Matters

Neuropsychiatric disorders lack objective biomarkers, making diagnosis and treatment monitoring largely subjective. If extracellular vesicles carry cannabinoid-related biomarkers that reflect brain state, blood-based tests could eventually help personalize treatment for conditions like depression and schizophrenia.

The Bigger Picture

This represents a convergence of two rapidly growing fields: cannabinoid science and extracellular vesicle biology. If the proposed framework holds up, it could transform both how we diagnose neuropsychiatric conditions and how we develop cannabinoid-based treatments.

What This Study Doesn't Tell Us

This is a hypothesis-driven review, not a systematic analysis. The proposed framework is largely theoretical and requires extensive experimental validation. The interaction between cannabinoids and extracellular vesicles is still in early stages of research.

Questions This Raises

  • ?Can EV-based biomarkers predict individual responses to cannabinoid therapy?
  • ?Do chronic cannabis users show altered EV profiles that correlate with psychiatric symptoms?

Trust & Context

Key Stat:
Bidirectional relationship between cannabinoids and extracellular vesicles identified
Evidence Grade:
Hypothesis-driven narrative review synthesizing emerging evidence. The proposed framework is novel but largely theoretical.
Study Age:
Published in 2025.
Original Title:
Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review.
Published In:
Pharmaceuticals (Basel, Switzerland), 18(12) (2025)
Database ID:
RTHC-07055

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

What are extracellular vesicles?

Tiny membrane-bound packages that cells release to communicate with other cells. They carry proteins, RNA, and lipids that reflect the state of the cell that produced them, making them potential biomarkers.

Could this lead to a blood test for psychiatric conditions?

That is the long-term hope. If extracellular vesicles in the blood carry cannabinoid-related markers that reflect brain state, a simple blood draw could theoretically help diagnose or monitor psychiatric conditions. This is still far from clinical application.

Read More on RethinkTHC

Cite This Study

RTHC-07055·https://rethinkthc.com/research/RTHC-07055

APA

Marques, Bruno L; Lirio, Pedro H C; Vicente, Maria A; Unzueta-Larrinaga, Paula; Urigüen, Leyre; Campos, Alline C. (2025). Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review.. Pharmaceuticals (Basel, Switzerland), 18(12). https://doi.org/10.3390/ph18121817

MLA

Marques, Bruno L, et al. "Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review.." Pharmaceuticals (Basel, 2025. https://doi.org/10.3390/ph18121817

RethinkTHC

RethinkTHC Research Database. "Cannabinoids and Extracellular Vesicles as Potential Biomark..." RTHC-07055. Retrieved from https://rethinkthc.com/research/marques-2025-cannabinoids-and-extracellular-vesicles

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.